ITeos Therapeutics Inc Forecast, price target & analysts
ITeos Therapeutics Inc Target price 2025 - Analyst rating & recommendation
ITeos Therapeutics Inc Classifications & Recommendation:
ITeos Therapeutics Inc Price Target
| Target Price | $18.80 |
| Price | $5.70 |
| Potential |
229.83%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target ITeos Therapeutics Inc 2026 .
The average ITeos Therapeutics Inc target price is $18.80.
This is
229.83%
register free of charge
$25.00
338.60%
register free of charge
$15.00
163.16%
register free of charge
|
|
| A rating was issued by 5 analysts: 5 Analysts recommend ITeos Therapeutics Inc to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the ITeos Therapeutics Inc stock has an average upside potential 2026 of
229.83%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 35.00 | 7.40 |
| 177.78% | 78.86% | |
| EBITDA Margin | -452.26% | -2,202.70% |
| 62.06% | 387.05% | |
| Net Margin | -346.89% | -1,420.79% |
| 62.06% | 309.58% |
5 Analysts have issued a sales forecast ITeos Therapeutics Inc 2025 . The average ITeos Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast ITeos Therapeutics Inc 2025 . The average ITeos Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2 ITeos Therapeutics Inc Analysts have issued a net profit forecast 2025. The average ITeos Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.32 | -2.88 |
| 5.40% | 13.25% | |
| P/E | negative | |
| EV/Sales | negative |
2 Analysts have issued a ITeos Therapeutics Inc forecast for earnings per share. The average ITeos Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
ITeos Therapeutics Inc...
Current ITeos Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 16 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Dec 19 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 13 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 15 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 16 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Dec 19 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 13 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 15 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
